Aetna Fertility Billing: Coverage Rules and Authorization Tips

Aetna insures a significant share of U.S. fertility patients through its commercial, exchange, and Medicare Advantage products. Getting Aetna fertility billing right requires understanding three variables that interact with every claim: the Clinical Policy Bulletin (CPB) that defines medical necessity for the member's specific plan type, the prior authorization requirements that apply to ART procedures, and whether the member's group health plan is fully insured — governed by Aetna's CPB and applicable state mandates — or self-funded, where the employer's plan document controls coverage and may diverge substantially from Aetna's standard policy. Getting any one of these variables wrong can produce a denial at the authorization stage, at adjudication, or both.

Aetna Clinical Policy Bulletins for Fertility Services

Aetna publishes Clinical Policy Bulletins (CPBs) that define covered fertility services, medical necessity criteria, and documentation requirements for fully insured plans. Billing staff and authorization coordinators should know the relevant CPBs by number because Aetna reviewers cite them in every adverse determination letter. Each CPB shows a Last Review and a Next Review date at the top, and Aetna revises bulletins on its own schedule, so always open the current version at aetna.com/cpb before submitting an authorization — the policy version in effect on the date of service controls coverage, not the version your team printed out six months ago.

• CPB 0327 – Infertility: Aetna's primary fertility policy for fully insured plans. Defines the diagnostic criteria for infertility, step-therapy requirements (a trial of egg-sperm contact, then ovulation-induction cycles before IVF), bypass diagnoses, and covered ART service categories. This is the document your authorization staff must know before submitting any IVF or IUI auth.
• CPB 0358 – Invasive Prenatal Diagnosis of Genetic Diseases: CPB 0327 routes preimplantation genetic testing here. PGT-M is covered for members with an ART benefit when the CPB 0358 indications are met, and PGT-SR is medically necessary when a reproductive partner carries a balanced translocation or inversion. PGT-A is listed as experimental, investigational, or unproven, including for IVF optimization, prior failed IVF cycles, and recurrent miscarriage. Do not assume a PGT request will be approved simply because IVF is authorized.
• GIFT and ZIFT: these do not have a separate bulletin. CPB 0327 treats GIFT and ZIFT as medically necessary alternatives to IVF for female factor infertility and as experimental for male factor or unexplained infertility. Most modern fertility practices do not perform these procedures.
• Infertility drugs: CPB 0327 itself requires precertification of Gonal-F, Follistim AQ, Menopur, Cetrotide, ganirelix, Novarel, Pregnyl, Ovidrel, and chorionic gonadotropin in applicable plan designs. Aetna Specialty Pharmacy Guideline Management may bypass its medical necessity review when the related infertility procedure has been approved, but some plans require that review for every infertility drug, so check the member's plan before assuming the procedure approval covers the medications.

Prior Authorization Requirements by Service Type

Aetna requires prior authorization for most ART procedures on fully insured commercial plans. The table below reflects Aetna's standard authorization requirements under CPB 0327; always verify against the member's specific plan, as self-funded employer groups may impose different or additional authorization requirements not reflected in the standard policy.

Step Therapy: What CPB 0327 Requires Before Aetna Will Authorize IVF

For fully insured Aetna plans without a state fertility mandate override, CPB 0327 requires documentation of failed conservative treatment before IVF authorization will be issued. Aetna's Infertility Services Precertification Information Request Form (GR-69375-2) asks, for each prior ovulation-induction cycle, for the medication taken, the month and year completed, the outcome, and whether the cycle used IUI or timed intercourse. For an initial ART request it also asks for all previous IUI cycles, time trying to conceive or the history that led to the diagnosis, sterilization history, and cycle day 3 bloodwork, and it warns that failing to submit all requested medical records may delay review or result in denial. CPB 0327 requires the egg-sperm contact trial to be documented in the medical record, so send the cycle records themselves rather than a referral summary stating the patient "completed 3 IUI cycles." If the IUI cycles were performed at a different practice, obtain the complete records before submitting the IVF authorization.

• Trial of egg-sperm contact: under 35, 12 months of regular intravaginal insemination or 4 cycles of timed intrauterine or intracervical insemination; 35 and older, 6 months or 3 timed cycles. It must be documented in the medical record and applies regardless of sexual orientation or partner status. CPB 0327 has no age at which this trial is waived.
• Ovulation induction before IVF: 3 failed cycles of oral or injectable ovulation induction, with or without insemination, for patients 37 and under; no ovulation-induction trial for patients 38 and older. Oral cycles satisfy the requirement, and oral ovulation induction may run concurrently with the egg-sperm contact cycles. Document each cycle individually with stimulation protocol, peak response, insemination parameters if any, and failed cycle confirmation.
• Bilateral tubal disease (ICD-10 N97.1), such as bilateral obstruction, absence or hydrosalpinges: waives the egg-sperm contact requirement for IVF. Attach the HSG or diagnostic laparoscopy results showing bilateral disease.
• Azoospermia or severe male factor (ICD-10 N46.01, N46.11): the CPB 0327 appendix defines severe deficits as under 10 million total motile sperm per ejaculate (unwashed) or under 3 million (washed) on 2 analyses at least 2 weeks apart, or under 4% normal forms by Kruger strict morphology. Attach both semen analysis reports with the authorization submission.
• Poor ovarian reserve (CPB 0327 lists E28.39 and E28.310–E28.319 for it): not a waiver of the egg-sperm contact or ovulation-induction requirement. CPB 0327 measures ovarian reserve by day-3 FSH and states no AMH or antral follicle count cutoff. On plans that exclude own-egg ART for poor ovarian reserve, day-3 FSH must be below 19 mIU/mL on the most recent test under 40 and on every prior unmedicated test at 40 and older, and patients 39 and older need a day-3 FSH from the prior 6 months. Attach the lab report with the numeric FSH value and draw date.
• Premature ovarian failure (day-3 FSH above 19 mIU/mL before age 40): not on the waiver list. CPB 0327 treats ART as medically necessary for it until age 45 and lists it as an indication for oocyte donation; on plans with the poor-ovarian-reserve exclusion, own-egg ART requires a most recent day-3 FSH below 19 mIU/mL.
• Failure to conceive after pelvic surgery that restored normal anatomy (e.g., myomectomy, adhesion or septum resection, tubal reconstruction): IVF after 6 months of egg-sperm contact under 40, or 3 months at 40 and older. Unilateral hydrosalpinx: after 12 months under 40, or 6 months at 40 and older. Attach operative, pathology and radiology reports as applicable.
• Endometriosis stage 3 or 4, and inadvertent ovarian hyperstimulation under age 38 during preparation for a planned stimulated cycle (estradiol above 1,000 pg/mL plus more than 3 follicles over 16 mm, or 4 to 8 follicles over 14 mm): both are listed IVF waivers. ICD-10-CM does not encode endometriosis stage, so attach the operative report that stages it.

ICD-10 Code Selection for Aetna Fertility Claims

ICD-10 code selection is not a clerical function in Aetna fertility billing — it directly determines whether step-therapy applies, which bypass diagnoses qualify the patient for direct IVF authorization, and how the authorization routes internally (nurse reviewer versus medical director). The REI physician must confirm the primary diagnosis code before every authorization submission, not just the clinical description. A code mismatch between what the physician documented and what the billing team submitted is both a compliance risk and a denial risk.

Fully Insured vs. Self-Funded Plans: Why Plan Type Changes Everything

Aetna administers both fully insured plans — where Aetna bears the insurance risk and CPB 0327 controls coverage — and self-funded employer plans — where the employer bears the financial risk and Aetna administers claims as a third-party administrator. Self-funded plans are governed by the federal ERISA statute, not by state insurance law, which means state fertility mandates do not apply to them regardless of where the employer or the employee is located. A member with an Aetna insurance card whose employer has a self-funded plan may have zero fertility coverage even if they live in a state with an IVF mandate — because the mandate only applies to Aetna's fully insured products, not to the employer's self-funded plan document.

Identifying plan type before submitting an authorization is not optional — it determines whether CPB 0327 applies to the member at all. Self-funded plan documents are not publicly available; the practice must request the fertility benefit section of the Summary Plan Description (SPD) from the member's HR department, or call Aetna provider services and ask specifically whether the group number is a fully insured or ASO (Administrative Services Only) arrangement. The member's insurance card may carry an ASO or Administrative Services notation. Submitting a complete IVF authorization package for a self-funded plan member whose employer has excluded fertility coverage results in a denial that no amount of clinical documentation will overturn — because the denial is based on the plan document exclusion, not on a clinical determination, and the plan document controls under ERISA.

Common Aetna Fertility Denial Reasons and Prevention Strategies

• No prior authorization obtained: Aetna denies claims for CPT 58970, 58974, 58976, and 89250 when no authorization was obtained in advance. These denials cannot typically be retro-authorized — the claim is written off. Build a trigger in your practice management system that blocks any ART procedure charge entry without a matching authorization number.
• Authorization obtained but CPT codes do not match the claim: The auth letter covers CPT 58970 and 58974 but the claim includes 89250 (embryology) and 89281 (ICSI), which were not listed on the authorization request. Pull the auth letter and compare it against every planned CPT code before the retrieval date — not after the claim is denied.
• Step-therapy documentation is incomplete: prior-cycle history submitted without the details Aetna's precertification form asks for — medication, month and year completed, outcome, and IUI versus timed intercourse for each ovulation-induction cycle. Obtain the cycle records from the treating practice before submission; CPB 0327 requires the egg-sperm contact trial to be documented in the medical record.
• Wrong ICD-10 code activates step-therapy: N97.9 submitted when the record supports a CPB 0327 waiver, such as bilateral tubal disease (N97.1) or azoospermia (N46.01). Confirm the specific ICD-10 code — not just the clinical description — with the REI physician before every authorization.
• Authorization expired before date of service: check the authorized service dates on Aetna's precertification response rather than assuming a standard validity period. If the cycle is delayed past the end date, update the existing request before the date of service. Build an expiration alert for all open Aetna IVF authorizations in your scheduling or authorization tracking system.
• FET assumed to be covered under original IVF authorization: The practice assumes the frozen embryo transfer is covered under the retrieval authorization from a prior cycle. Aetna's infertility precertification form lists Frozen Embryo Transfer (FET) as its own requested service, separate from Complete IVF and IVF Freeze All, and states that prior treatment approval does not guarantee approval for ongoing or future treatment. Confirm whether the FET needs its own precertification and, if it does, request it before the frozen transfer cycle starts, not at transfer.
• Self-funded plan excludes fertility coverage: No clinical documentation, appeal, or peer-to-peer review will overturn a plan document exclusion under ERISA. Identify this before the consultation, not after the claim is denied and the service has already been rendered.
• Lab component denied as unauthorized: 89250 (IVF culture and fertilization) requires authorization. Practices that list only 58970 and 58974 on the authorization request and then bill 89250 separately on the laboratory claim are submitting an unauthorized service — it will be denied and the appeal window is limited.

Authorization Submission Protocol for Aetna IVF and FET Cycles

A standardized Aetna authorization submission protocol reduces denial rates more reliably than any other single intervention in Aetna fertility billing. The following steps reflect current best practices for Aetna fully insured commercial plans; adapt as needed for specific employer group plan designs identified during benefit verification.

• Submit the IVF precertification request early. Aetna's infertility precertification form asks the attending physician to complete it at least 15 days before the planned treatment start date — the start of the treatment cycle, not the retrieval date. The form does not state a review turnaround time, so build in lead time and track every pending request.
• List all anticipated CPT codes on the authorization request simultaneously: 58970 (oocyte retrieval), 89250 (fertilization and culture), 89258 (cryopreservation if applicable), 58974 (fresh embryo transfer if planned), 89280 or 89281 (ICSI if applicable). Do not submit retrieval codes first and add embryology codes in a second request — the second submission often generates a separate authorization number, creating a code mismatch at claim adjudication.
• Where the plan requires FET precertification, submit it as its own request (the form's Frozen Embryo Transfer service) before each frozen transfer cycle begins. Include CPT 58976 (cryo-thaw embryo transfer) and 89352 (thawing of cryopreserved embryo) on the FET authorization. Do not submit the FET auth at the same time as the retrieval auth months in advance — the approved date range may end before the FET cycle occurs.
• Attach clinical documentation proactively with every submission: the physician's criterion-specific letter of medical necessity, complete IUI cycle records for each required cycle, day-3 FSH lab report with numeric value and draw date when ovarian reserve is at issue, semen analysis reports for male-factor waivers, and the patient's IVF treatment plan. Aetna's precertification form states that failing to submit all requested medical records may result in delay of review or denial of coverage.
• Follow up on every submitted authorization within 5 business days. Do not assume silence means the request is moving — missing records can delay review or lead to a denial. Assign a team member to check the status of every pending auth at the 5-business-day mark on Availity, the provider portal Aetna's form names for submitting precertification requests, uploading clinical documentation, checking status, and changing existing requests.
• Obtain and retain the written authorization letter — not just the verbal authorization number. Verify that the letter explicitly lists the approved CPT codes, the approved ICD-10 codes, the authorized service date range, and the authorizing facility or provider. A verbal auth number without a written confirmation provides limited protection at adjudication if code or date discrepancies arise.

Aetna Fertility Benefit Verification Checklist

Complete this checklist at the initial consultation for every new Aetna patient, and reverify at the start of each treatment cycle. Benefit information changes at plan renewal, which is typically January 1 for most employer groups but may occur on a different anniversary date — a benefit that was accurate in January may be materially different if the employer renewed mid-year or switched products.

• Plan type: fully insured or self-funded (ASO)? If self-funded, request the SPD fertility benefit section from the employer before scheduling any treatment — do not proceed on the assumption that Aetna's standard CPB applies.
• State mandate applicability: Is the member enrolled in a fully insured plan in a state with a fertility insurance mandate? Confirm that coverage for this group reflects the current mandate requirements, including cycle limits, diagnostic criteria, and covered services.
• IVF benefit design: Is IVF covered? How many lifetime cycles? Is there a per-cycle or lifetime dollar maximum? Does the plan count a cancelled cycle as a used benefit cycle?
• FET benefit: Are frozen embryo transfers covered under the same benefit allocation as IVF retrievals, or are they counted separately? Some Aetna plans count each FET as an independent cycle against the lifetime maximum.
• Step-therapy requirement: Does the plan require IUI cycles before IVF? How many? Which bypass diagnoses are recognized under this specific plan?
• Network status: Is the fertility practice in-network for this specific Aetna product? Is the embryology laboratory in-network and on a separate contract? Confirm the lab's network status for the member's specific Aetna product separately; do not infer it from the practice's status.
• Pharmacy vs. medical benefit for injectable medications: Are gonadotropins covered under the medical benefit (J-codes billed by the practice) or under the pharmacy benefit (patient uses a specialty pharmacy)? This varies widely across Aetna products and employer group designs.
• Deductible and out-of-pocket status: What is the current year-to-date deductible accumulation? What is the out-of-pocket maximum and current accumulation? What is the patient's coinsurance responsibility for ART services after the deductible is met?
• Coordination of benefits: Is Aetna primary or secondary? Does a secondary payer exist? If COB applies, verify the order of benefits and the secondary payer's fertility benefit before submitting any claims.

What Aetna Gets Right — and Where Practices Lose Revenue

Aetna's fertility policies are more transparent than many commercial payers — the CPBs are publicly accessible, the step-therapy criteria are documented in writing, and the bypass diagnoses are explicitly listed. Practices that invest in reading the current CPB 0327 before each authorization cycle, building payer-specific authorization checklists that mirror Aetna's CPT code requirements, and training staff to identify plan type before any authorization submission remove the most common avoidable reasons for Aetna authorization and claim denials. Practices that treat Aetna like a generic commercial payer — submitting generic auth requests, using N97.9 for every patient, and assuming one authorization covers all service codes — invite preventable denials. The documentation Aetna requires is demanding but consistent. Meeting it front-end is far less costly than recovering revenue on the back end.